Jiangxi Institute of Biological Products Inc. (HKG:6915)
Hong Kong · Delayed Price · Currency is HKD 10.74
+0.45 (4.37%)
At close: Oct 7, 2026
HKG:6915 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| 219 | 235.41 | 220.76 | 198.02 | |
Revenue Growth | - | 6.64% | 11.48% | - |
Cost of Revenue | 52.32 | 54.72 | 65.62 | 63.72 |
Gross Profit | 166.67 | 180.69 | 155.14 | 134.31 |
Selling, General & Admin | 52.84 | 53.45 | 59.21 | 62.19 |
Research & Development | 25.42 | 23.7 | 13.68 | 24.23 |
Operating Expenses | 79.95 | 79.4 | 72.64 | 86.26 |
Operating Income | 86.72 | 101.28 | 82.5 | 48.04 |
Interest Expense | -0.04 | -0.03 | -2.23 | -0.67 |
Interest & Investment Income | 0.15 | 0.17 | 0.31 | 0.28 |
Other Non Operating Income (Expenses) | -20.95 | -14.43 | -0.64 | 2.11 |
EBT Excluding Unusual Items | 65.89 | 86.99 | 79.95 | 49.76 |
Gain (Loss) on Sale of Investments | 0.24 | 0.13 | 0.11 | 0.26 |
Gain (Loss) on Sale of Assets | -0.01 | 3.76 | -0.03 | 0.06 |
Asset Writedown | 16.76 | 18.38 | 11.63 | 13.5 |
Other Unusual Items | - | - | 0.11 | - |
Pretax Income | 82.88 | 109.26 | 91.77 | 63.59 |
Income Tax Expense | 10.55 | 14.47 | 16.63 | 8.11 |
Earnings From Continuing Operations | 72.32 | 94.79 | 75.14 | 55.48 |
Minority Interest in Earnings | - | - | - | 0.01 |
Net Income | 72.32 | 94.79 | 75.14 | 55.49 |
Net Income to Common | 72.32 | 94.79 | 75.14 | 55.49 |
Net Income Growth | - | 26.16% | 35.40% | - |
Shares Outstanding (Basic) | 272 | 272 | 272 | 272 |
Shares Outstanding (Diluted) | 272 | 272 | 272 | 272 |
Shares Change | - | - | - | - |
EPS (Basic) | 0.27 | 0.35 | 0.28 | 0.20 |
EPS (Diluted) | 0.26 | 0.35 | 0.28 | 0.20 |
EPS Growth | - | 26.16% | 35.40% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | 29.39 | 20.79 | 87.41 | 38.19 |
Free Cash Flow Per Share | 0.11 | 0.08 | 0.32 | 0.14 |
Gross Margin | 76.11% | 76.75% | 70.28% | 67.82% |
Operating Margin | 39.60% | 43.03% | 37.37% | 24.26% |
Profit Margin | 33.02% | 40.27% | 34.04% | 28.02% |
Free Cash Flow Margin | 13.42% | 8.83% | 39.60% | 19.28% |
EBITDA | 97.82 | 112.27 | 93.38 | 59.01 |
EBITDA Margin | 44.67% | 47.69% | 42.30% | 29.80% |
D&A For EBITDA | 11.1 | 10.99 | 10.88 | 10.97 |
EBIT | 86.72 | 101.28 | 82.5 | 48.04 |
EBIT Margin | 39.60% | 43.03% | 37.37% | 24.26% |
Effective Tax Rate | 12.73% | 13.24% | 18.12% | 12.76% |